Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Overview of attention for article published in Cochrane database of systematic reviews, December 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 10 tweeters

facebook: 1 Facebook page
wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 104 Mendeley

Summary Policy documents Twitter Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Abiraterone Acetate for Metastatic Castrate Sensitive Prostate Cancer

Cited by Canadian Agency for Drugs and Technologies in Health on 26 May 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Cochrane Database of Systematic Reviews